KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AbbVie (ABBV) Operating Expenses (2016 - 2025)

AbbVie (ABBV) has disclosed Operating Expenses for 14 consecutive years, with $12.1 billion as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 27.23% to $12.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $46.1 billion through Dec 2025, down 2.36% year-over-year, with the annual reading at $46.1 billion for FY2025, 2.36% down from the prior year.
  • Operating Expenses for Q4 2025 was $12.1 billion at AbbVie, down from $13.9 billion in the prior quarter.
  • The five-year high for Operating Expenses was $16.6 billion in Q4 2024, with the low at $8.8 billion in Q1 2022.
  • Average Operating Expenses over 5 years is $10.7 billion, with a median of $10.1 billion recorded in 2021.
  • The sharpest move saw Operating Expenses skyrocketed 77.57% in 2021, then dropped 27.23% in 2025.
  • Over 5 years, Operating Expenses stood at $9.8 billion in 2021, then fell by 1.97% to $9.6 billion in 2022, then increased by 15.46% to $11.1 billion in 2023, then skyrocketed by 49.4% to $16.6 billion in 2024, then fell by 27.23% to $12.1 billion in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $12.1 billion, $13.9 billion, and $10.5 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.